

Jae-Hyun Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11906362/publications.pdf>

Version: 2024-02-01

58
papers

3,333
citations

147801

31
h-index

149698

56
g-index

58
all docs

58
docs citations

58
times ranked

5819
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. <i>Cancer Medicine</i> , 2020, 9, 324-334.	2.8	14
2	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020, 55, 1161-1168.	2.4	11
3	The GALNT6-GALS3BP axis promotes breast cancer cell growth. <i>International Journal of Oncology</i> , 2020, 56, 581-595.	3.3	9
4	Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 507-516.	4.1	22
5	TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. <i>Oncolmmunology</i> , 2019, 8, e1588085.	4.6	17
6	MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells. <i>Oncology Reports</i> , 2019, 41, 2540-2548.	2.6	12
7	Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2019, 8, e1568813.	4.6	31
8	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5357-5367.	7.0	70
9	<sc>CD8</sc> lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. <i>Cancer Reports</i> , 2018, 1, e1002.	1.4	8
10	Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX. <i>Oncotarget</i> , 2018, 9, 31820-31831.	1.8	17
11	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. <i>Oncotarget</i> , 2018, 9, 11009-11019.	1.8	44
12	Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells. <i>Neoplasia</i> , 2018, 20, 1038-1044.	5.3	15
13	Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment. <i>Human Molecular Genetics</i> , 2018, 27, 2671-2677.	2.9	11
14	The era of immunogenomics/immunopharmacogenomics. <i>Journal of Human Genetics</i> , 2018, 63, 865-875.	2.3	15
15	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2018, 201, 1967-1974.	0.8	22
16	Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of <i>in vitro</i> expanded populations in head and neck cancer. <i>Oncotarget</i> , 2018, 9, 3805-3814.	1.8	6
17	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. <i>Oncotarget</i> , 2018, 9, 18985-18996.	1.8	83
18	WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. <i>Scientific Reports</i> , 2017, 7, 40664.	3.3	36

#	ARTICLE	IF	CITATIONS
19	Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. <i>Oncolmmunology</i> , 2017, 6, e1278330.	4.6	54
20	GALNT6 Stabilizes GRP78 Protein by O-glycosylation and Enhances its Activity to Suppress Apoptosis Under Stress Condition. <i>Neoplasia</i> , 2017, 19, 43-53.	5.3	23
21	Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2017, 23, 4897-4907.	7.0	21
22	Characterization of the cryoablation-induced immune response in kidney cancer patients. <i>Oncolmmunology</i> , 2017, 6, e1326441.	4.6	34
23	<sc>TOPK</sc> (Tâ€œ<sc>LAK</sc> cellâ€œoriginated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. <i>Cancer Science</i> , 2017, 108, 488-496.	3.9	28
24	Effects of <sc>SMYD</sc>2â€œmediated <sc>EML</sc>4â€œ<sc>ALK</sc> methylation on the signaling pathway and growth in nonâ€œsmallâ€œcell lung cancer cells. <i>Cancer Science</i> , 2017, 108, 1203-1209.	3.9	38
25	Development of small molecular compounds targeting cancer stem cells. <i>MedChemComm</i> , 2017, 8, 73-80.	3.4	14
26	p53-independent p21 induction by MELK inhibition. <i>Oncotarget</i> , 2017, 8, 57938-57947.	1.8	35
27	Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. <i>Oncotarget</i> , 2017, 8, 62029-62038.	1.8	28
28	Critical roles of SMYD2-mediated β -catenin methylation for nuclear translocation and activation of Wnt signaling. <i>Oncotarget</i> , 2017, 8, 55837-55847.	1.8	37
29	Intratumoral expression levels of <i>PD-L1</i>, <i>GZMA</i>, and <i>HLA-A</i> along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. <i>Oncolmmunology</i> , 2016, 5, e1204507.	4.6	107
30	Myasthenic crisis and polymyositis induced by one dose of nivolumab. <i>Cancer Science</i> , 2016, 107, 1055-1058.	3.9	176
31	Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. <i>Neoplasia</i> , 2016, 18, 265-272.	5.3	27
32	T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6110-6117.	7.0	63
33	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478.	3.3	32
34	Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 13621-13633.	1.8	41
35	Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. <i>Oncotarget</i> , 2016, 7, 17652-17664.	1.8	44
36	T-LAK cell-originated protein kinase presents a novel therapeutic target in <i>FLT3</i>-ITD mutated acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 33410-33425.	1.8	22

#	ARTICLE	IF	CITATIONS
37	Presence of Insulin-Like Growth Factor Binding Proteins Correlates With Tumor-Promoting Effects of Matrix Metalloproteinase 9 in Breast Cancer. <i>Neoplasia</i> , 2015, 17, 421-433.	5.3	28
38	Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. <i>Oncolmmunology</i> , 2015, 4, e1030561.	4.6	52
39	TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. <i>Science Translational Medicine</i> , 2014, 6, 259ra145.	12.4	95
40	Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance. <i>Cancer Cell</i> , 2012, 21, 488-503.	16.8	419
41	Polypeptide N-acetylgalactosaminyltransferase 6 Disrupts Mammary Acinar Morphogenesis through O-glycosylation of Fibronectin. <i>Neoplasia</i> , 2011, 13, 320-IN10.	5.3	88
42	Critical roles of Tâ€LAK cellâ€originated protein kinase in cytokinesis. <i>Cancer Science</i> , 2010, 101, 403-411.	3.9	68
43	Critical Roles of Mucin 1 Glycosylation by Transactivated Polypeptide<i>N</i>-Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis. <i>Cancer Research</i> , 2010, 70, 2759-2769.	0.9	146
44	Activation of an Estrogen/ Estrogen Receptor Signaling by BIG3 Through Its Inhibitory Effect on Nuclear Transport of PHB2/REA in Breast Cancer. <i>Nature Precedings</i> , 2009, , .	0.1	1
45	Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells. <i>Cancer Research</i> , 2009, 69, 8752-8760.	0.9	106
46	Involvement of Gâ€patch domain containing 2 overexpression in breast carcinogenesis. <i>Cancer Science</i> , 2009, 100, 1443-1450.	3.9	41
47	Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. <i>Cancer Science</i> , 2009, 100, 1468-1478.	3.9	54
48	Involvement of kinesin family member 2C/mitotic centromereâ€associated kinesin overexpression in mammary carcinogenesis. <i>Cancer Science</i> , 2008, 99, 62-70.	3.9	94
49	Establishment and characterization of cell lines from three human thyroid carcinomas: Responses to all-trans-retinoic acid and mutations in the BRAF gene. <i>Molecular and Cellular Endocrinology</i> , 2007, 264, 118-127.	3.2	25
50	Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. <i>Breast Cancer Research</i> , 2007, 9, R17.	5.0	150
51	Microarray Gene Expression Profiling for Predicting Complete Response to Preoperative Chemoradiotherapy in Patients with Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1342-1353.	1.3	127
52	PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer. <i>Cancer Research</i> , 2006, 66, 9186-9195.	0.9	164
53	A functional polymorphism (-347 G->GA) in the E-cadherin gene is associated with colorectal cancer. <i>Carcinogenesis</i> , 2004, 25, 2173-2176.	2.8	36
54	Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays. <i>Clinical Cancer Research</i> , 2004, 10, 272-284.	7.0	169

#	ARTICLE	IF	CITATIONS
55	The E-cadherin α 347G α 'GA promoter polymorphism and its effect on transcriptional regulation. Carcinogenesis, 2004, 25, 895-899.	2.8	62
56	Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Human Genetics, 2003, 114, 118-120.	3.8	61
57	Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Human Mutation, 2002, 20, 235-235.	2.5	47
58	WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget, 0, 7, 42527-42538.	1.8	33